Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXH254 combination therapy in previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
2024-511934-11-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of naporafenib in melanoma (5 arms), sponsored by Novartis. Primary endpoint: Confirmed objective response rate (ORR) per RECIST v1.1 (local assessment). Planned start Jun 2024; status: authorised.
02
Drugs
naporafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-511934-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511934-11-00.